Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Zelai Wu"'
Autor:
Xiaolong Miao, Peng Jiang, Xiaotong Zhang, Xinqiang Li, Zelai Wu, Yuancong Jiang, Han Liu, Weixun Xie, Xinwei Li, Bingfeng Shi, Jinzhen Cai, Weihua Gong
Publikováno v:
Microbiology Spectrum, Vol 12, Iss 5 (2024)
ABSTRACTSolid organ transplantation is a crucial treatment for patients who have reached the end stage of heart, lung, kidney, or liver failure. However, the likelihood of developing cancer post-transplantation increases. Additionally, primary malign
Externí odkaz:
https://doaj.org/article/696db03d4ba94ada872e42cb3df270ef
Autor:
Chengyu Hu, Bixian Luo, Bo Hong, Mingqi Zhang, Zelai Wu, Xiuliang Zhu, Fengming Luan, Yi Huang, Weihua Gong
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Paragangliomas (PGLs) are rare neuroendocrine tumors which overproduce catecholamines (CAs). They are extra-adrenal, catecholamine-secreting tumors occurring outside the adrenal glands. Gastric PGLs originating from extra-adrenal paraganglia are exce
Externí odkaz:
https://doaj.org/article/fb5a5cedaa104d8eb505130440f0b9a0
Publikováno v:
Heliyon, Vol 9, Iss 11, Pp e22093- (2023)
Bromodomain and extraterminal domain protein inhibitors have shown therapeutic promise in hepatocellular carcinoma. However, resistance to bromodomain and extraterminal domain protein inhibitors has emerged in preclinical trials, presenting an immens
Externí odkaz:
https://doaj.org/article/39044da99540451f9881a55e596ecc37
Autor:
Yao Wang, Xiaolong Miao, Yuancong Jiang, Zelai Wu, Xuhang Zhu, Han Liu, Xiaoying Wu, Jinzhen Cai, Xianfeng Ding, Weihua Gong
Publikováno v:
Cell Death and Disease, Vol 13, Iss 2, Pp 1-9 (2022)
Abstract Hepatocellular carcinoma (HCC) still ranks among the top cancers worldwide with high incidence and mortality. Due to abnormal activation of the PI3K/AKT/mTOR signalling pathway in HCC, targeting this pathway represents a potential therapeuti
Externí odkaz:
https://doaj.org/article/126c4887249d490a8d8d5620bc6cb46c
Autor:
Xiaolong Miao, Chen Liu, Yuancong Jiang, Yao Wang, Deqiang Kong, Zelai Wu, Xinyi Wang, Rui Tian, Xing Yu, Xuhang Zhu, Weihua Gong
Publikováno v:
Cell Death and Disease, Vol 12, Iss 11, Pp 1-12 (2021)
Externí odkaz:
https://doaj.org/article/980fe2106c9a41e580cf6301ce67beda
Autor:
Zelai Wu, Xiaolong Miao, Yuancong Jiang, Deqiang Kong, Han Liu, Weixun Xie, Bingfeng Shi, Weihua Gong
Publikováno v:
The Journal of Thoracic and Cardiovascular Surgery.
Publikováno v:
European Cytokine Network. 32:73-82
Inflammatory bowel disease (IBD), including Crohn disease and ulcerative colitis, with multifactorial etiologies has led to a global health-associated burden in many countries. Substantial efforts are devoted to understand the pathogenesis, behaviora
Publikováno v:
Microbiology spectrum. 10(4)
Cardiac allograft rejection remains a major factor limiting long-term engraftment after transplantation. A novel phosphoinositide 3-kinase (PI3K)/mTOR dual inhibitor, BEZ235, prolonged cardiac allograft survival by effectively suppressing activation
Publikováno v:
Immunology.
Immunotherapy with immune checkpoint inhibitors (ICIs), including antibodies against programmed cell death protein-1 (PD-1) and its receptor programmed cell death ligand-1 (PD-L1), represents a promising systematic treatment for advanced human malign
Publikováno v:
Transplantation proceedings. 54(7)
BEZ235, a dual PI3K/mTOR inhibitor, has shown a critical impact in the treatment of cancers, with the ability to induce autophagy. However, the effects of BEZ235 in heart transplant have been rarely investigated. The aim of this study was to evaluate